PDS Biotechnology updates August 2025 presentation

PDS Biotechnology Corporation filed a current report to note that it has updated its corporate presentation deck.

Rhea-AI Filing Summary

PDS Biotechnology Corporation filed a current report to note that it has updated its corporate presentation deck. The new presentation, dated August 2025, is provided as Exhibit 99.1 and is incorporated by reference, meaning it is intended to be used as part of the company’s formal public disclosures. The filing does not describe financial results or new transactions, but signals that the company is refreshing the materials it uses to communicate its business, pipeline, and strategy to the market.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PDSB report in this 8-K filing?

PDS Biotechnology Corporation reported that it updated its corporate presentation deck and filed the new version, dated August 2025, as Exhibit 99.1.

Does the PDSB 8-K include new financial results or earnings data?

No. The 8-K describes an updated corporate presentation deck but does not provide financial results or earnings data in the excerpted content.

What exhibit did PDS Biotechnology add with this filing?

The company filed its updated corporate presentation as Exhibit 99.1, labeled "Corporate Presentation (August 2025)."

Who signed the PDSB current report related to the updated presentation?

The report was signed on behalf of PDS Biotechnology Corporation by Frank Bedu-Addo, Ph.D., its President and Chief Executive Officer.

On what date did PDS Biotechnology update its corporate presentation?

PDS Biotechnology updated its corporate presentation deck on August 25, 2025, which is also the date of the reportable event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/25/2025 - 04:06 PM Learn about SEC filing dates

false0001472091NASDAQ00014720912025-08-252025-08-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 25, 2025

PDS BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37568	26-4231384
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

303A College Road East, Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00033 per share	PDSB	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01 Other Events.

On August 25, 2025, the Company updated its corporate presentation deck.

A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Corporate Presentation (August 2025).
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PDS BIOTECHNOLOGY CORPORATION
Date:  August 25, 2025	By:	/s/ Frank Bedu-Addo, Ph.D.
	Name: Frank Bedu-Addo, Ph.D.
	Title: President and Chief Executive Officer